Research Reports

Key takeaways

Board amended Bylaws on April 22, 2026, revising Section 2.5 to permit director removal by majority vote of shares entitled to vote at any time, with or without cause.

Section 1.12 clarified that stockholder actions requiring a meeting cannot be taken without one, consistent with Certificate of Incorporation.

Amendments enhance shareholder rights to remove directors and reinforce meeting requirements for actions.

Full amended Bylaws attached as Exhibit 3.1.

Full analysis

The amendments to Halozyme Therapeutics, Inc.'s Bylaws, approved by the Board on April 22, 2026, directly impact corporate governance by expanding shareholder influence over the Board. The revision to Section 2.5 empowers holders of a majority of shares entitled to vote to remove directors at any time, with or without cause, potentially increasing accountability to shareholders and facilitating quicker changes in Board composition if dissatisfaction arises. The update to Section 1.12 reinforces procedural requirements by prohibiting actions that would typically occur at annual or special stockholder meetings from being taken without such a meeting, aligning with the company's Certificate of Incorporation. These changes could make the company more responsive to shareholder sentiment while maintaining structured decision-making processes, as detailed in the full Bylaws in Exhibit 3.1.

HALO · Halozyme Therapeutics, Inc.

Summary

Key takeaways

Full analysis